HGWM
SUPN icon

Harvest Group Wealth Management’s Supernus Pharmaceuticals SUPN Stock Holding History

Harvest Group Wealth Management’s Portfolio SUPN Stock Details SUPN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-27
Closed -$1K – 998
2019
Q1 		$1K Buy
+27
New +$1K ﹤0.01% 846

Other funds holding SUPN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CIP
Champlain Investment Partners Burlington, Vermont $7.88B AUM 6.82% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
RHJA
Rice Hall James & Associates San Diego, California $1.8B AUM 36.16% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return
NPIC
Neumeier Poma Investment Counsel Carmel, California $1.21B AUM 70.48% 1-Year Est. Return

Harvest Group Wealth Management's SUPN Position: Q2 2019 in Review

Harvest Group Wealth Management sold out of Supernus Pharmaceuticals (SUPN) in Q2 2019, closing a stake of 27 shares — an estimated $1K sold.

Harvest Group Wealth Management first reported a position in SUPN in Q1 2019 and held it in 1 quarter. The position peaked at $1K in Q1 2019. 272 funds tracked by Wall St. Rank hold SUPN as of Q2 2019.

  • Harvest Group Wealth Management reported no remaining Supernus Pharmaceuticals position as of Q2 2019 after selling out during the quarter.
  • Harvest Group Wealth Management sold 27 Supernus Pharmaceuticals shares in Q2 2019, an estimated $1K.
  • Harvest Group Wealth Management first reported a position in Supernus Pharmaceuticals in Q1 2019 and held it in 1 quarter.
  • Harvest Group Wealth Management's Supernus Pharmaceuticals position peaked at $1K in Q1 2019.
  • 272 funds tracked by Wall St. Rank held Supernus Pharmaceuticals as of Q2 2019.

Based on Harvest Group Wealth Management's 13F filing for Q2 2019, filed 31 Jul 2019.